PODD · NASDAQ
Healthcare · Medical Devices
$152.50
+2.40%
Close on Oct 29, 2026
Research data through 2026-10-29
Long-term research evidence only. No price targets, no trading signals, no recommendations.
Free research · no account required
Research data through Oct 29, 2026. Research is updated periodically, not in real time.
84
of 100 · stored research reading
Stored Quality research reads 84 of 100, in the strongest band of the covered universe. The underlying fundamental measurements behind this reading are consistent rather than mixed.
Quality research measures durability of the business itself from stored fundamentals: balance-sheet strength, profitability consistency and cash generation. It is a research reading, not a prediction of future returns.
How this is measured46
of 100 · stored research reading
Stored Fundamental Momentum research reads 46 of 100. Stored measurements classify recent reported fundamentals as deteriorating. This describes reported financial change already disclosed, with no forward-looking claim.
Fundamental Momentum research measures the direction of recently reported company fundamentals compared with the company's own history. It describes reported change, not future price movement.
How this is measured34
of 100 · stored research reading
Stored Capital Returns research reads 34 of 100, recorded as weak. No dividend is recorded for this company, so the reading rests on buybacks and dilution control. Share count has increased at about 0.8% a year in the stored window.
Capital Returns research measures how a company has actually returned cash to shareholders: dividend record, buyback effectiveness, dilution control and how those payments were funded.
How this is measuredStored ratios recorded at the last research date (2026-10-28). Valuation Intelligence remains research context and is not a validated allocation signal.
Learn the basics of valuationInvestor intelligence
The research below is part of Investor membership. Values are withheld from this page entirely — nothing premium is loaded into it. Start the free trial and the intelligence you asked for unlocks right here.
Investor
Unlock its Pro Investor Score and ranking across the research universe.
7 days · No credit card required
Investor
Unlock Risk Intelligence, Price Risk, and Market Confirmation.
7 days · No credit card required
Investor
Unlock the Pro Research Brief with What Changed & Why, research history and tensions.
7 days · No credit card required
Investor
Unlock Pro Investor Intelligence: disclosed professional-manager and insider activity beside company research.
7 days · No credit card required
Investor
Unlock Pro Investor AI to ask questions grounded in Pro Investor Academy research and evidence.
7 days · No credit card required
Investor
Save companies and monitor how their research changes over time.
7 days · No credit card required
Explore other companies in this industry. These are objective industry neighbours, not suggested alternatives.
Pro Investor Academy continuously applies its research rules across the eligible universe and surfaces a small number of investments for deeper research when they qualify.
Appears in
Membership means the company satisfied a published rule on the latest research build. It is not a recommendation.
Plain-English definitions, with the formula and the limitations of each measure.
In the company’s own words
Insulet Corporation ("we" or the "Company") is primarily engaged in the development, manufacture, and sale of its proprietary continuous insulin delivery systems for people with insulin-dependent diabetes. The Omnipod platform includes: the Omnipod 5 Automated Insulin Delivery System ("Omnipod 5"), the Omnipod DASH Insulin Management System ("Omnipod DASH"), and the Omnipod Insulin Management System ("Classic Omnipod").
We also produce pods for Amgen for use in the Neulasta Onpro kit, a delivery system for Amgen’s Neulasta to help reduce the risk of infection after intense chemotherapy.
Diabetes is a chronic, life-threatening disease for which there is no known cure. It is caused by the body’s inability to produce or effectively utilize the hormone insulin, which prevents the body from adequately regulating blood glucose levels. Glucose, the primary source of energy for cells, must be maintained at certain concentrations in the blood in order to permit optimal cell function and health. In people with diabetes, blood glucose levels fluctuate between very high levels, a condition known as hyperglycemia, and very low levels, a condition called hypoglycemia. Hyperglycemia can lead to serious short-term complications, such as confusion, vomiting, dehydration, and loss of consciousness and long-term complications, such as blindness, kidney disease, nervous system disease, occlusive vascular diseases, stroke, cardiovascular disease, or death. Hypoglycemia can lead to confusion, loss of consciousness, or death.
Type 1 diabetes is characterized by the body’s nearly complete inability to produce insulin. It is diagnosed throughout the age spectrum, with over half of newly diagnosed cases occurring in adulthood. Individuals with type 1 diabetes require daily insulin therapy to survive. We estimate that approximately 6 million people have type 1 diabetes in the countries we currently serve.
Quoted from the business section of this company’s 10-K filed February 18, 2026. Read the filing
General research only. Not personalized advice. Public filings may be delayed, amended, incomplete, or reflect positions that have changed since the reporting date.
